Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment
Valuation Down 42.3% Over Two Days
Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.
